Digital Telecytology for Triage of HPV-Positive Women in Cameroon
Recruiting
N/A
Interventional Study
Human Papillomavirus Infection
Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
Cervical Cancer Screening Methods
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 25 – 50
- Sex
- Female
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 1,800 (estimated)
- Sponsor
- University Hospital, Geneva · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyp…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old
* Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).
Exclusion Criteria:
* Pregnancy at the time of screening
* Previous hysterec…
Contacts